EUCTR2005-001074-27-DE进行中（未招募）不适用
A Multi-Centre, Double-Blind, Placebo-Controlled, Ascending-Dose, Clinical Trial of Intra-venous Microplasmin Administration in Patients with Acute Ischemic Stroke - MITI-IV
ThromboGenics Ltd.0 个研究点目标入组 40 人开始时间: 2006年5月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Acute ischemic stroke (defined as a measurable neurological deficit of sudden onset considered secondary to focal cerebral ischemia and not otherwise attributable to ICH or other condition), with onset within 12 hours before start of study drug administration(Onset is defined as the time the patient was last seen in a normal state, or bedtime for unwitnessed strokes occurring during the night).
- •2. Evidence of a perfusion defect of at least 2 cm in diameter, as assessed by MRI (PWI), corresponding to the acute stroke syndrome. The PWI will be assessed by relative mean transit time (MTT) images.
- •3. Ability to initiate study drug administration within 1 hour of completion of MRI and within 12 hours of stroke onset.
- •4. Male or female age 18-85 (inclusive)
- •5. Patients with baseline NIHSS >= 4 AND=< 22
- •6. Prior to inclusion in the study and following a full explanation of the nature and purpose of the study, the patient or the patient’s legal representative must consent/assent to participate by signing the Informed Consent document.
- •7. Women of child-bearing potential must have a negative pregnancy test prior to enrolment and be using a reliable form of contraception
- •8. Patients must be ambulatory prior to stroke onset.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •General exclusion criteria
- •1. Participation in another study with an investigational drug or device within the previous 30 days, prior participation in the present study, or planned participation in another trial within the timeframe of the current trial
- •2. Symptoms suggestive of subarachnoid hemorrhage, even if CT scan or MRI is negative for hemorrhage
- •3. Women known to be pregnant, lactating, or having a positive or indeterminate pregnancy test
- •Stroke related exclusion criteria
- •4. Neurological deficit that has led to stupor or coma (NIHSS Level Of Consciousness Item 1a score >or=2)
- •5. High clinical suspicion of septic embolus
- •6. Thrombosis involving cerebral veins
- •7. Rapidly improving neurological signs at any time before initiation of study drug administration
- •Imaging related exclusion criteria
- •8. Hemorrhagic transformation or intracerebral hemorrhage observed on baseline CT of the brain or gradient recalled echo (GRE) magnetic resonance imaging
- •9. CT or MRI evidence of nonvascular cause for the neurological symptoms
- •10. Ischemic lesion consistent with lacunar stroke
- •11. PWI not obtained or uninterpretable
- •12. No MTT defect corresponding to acute stroke deficit
- •13. Large hypodensity on CT involving > 1/3 of the MCA territory
- •14. Baseline DWI volume > 1/3 of the MCA territory
- •15. Signs of mass effect causing shift of midline structures on CT or MRI
- •16. Unable to undergo MRI (i.e., ferrous implants, cardiac pacemakers, agitation, claustrophobia or known sensitivity to MRI contrast agents)
- •Safety related exclusion criteria
- •17. Congenital or acquired coagulopathy causing either of the following
- •a. activated partial thromboplastin time prolongation greater than 2 seconds above
- •the ULN for local laboratory
- •b. International normalized ratio of 1.4 or more.
- •18. Uncontrolled hypertension defined as a systolic blood pressure > 180 mm Hg or a diastolic blood
- •pressure > =100 mm Hg on 3 separate occasions at least 10 minutes apart or requiring continuous
- •IV therapy.
- •19. History of stroke within the previous 3 months
- •20. Seizures at any time between stroke onset to planned initiation of study drug
- •21. History of intracranial hemorrhage
- •22. History of surgery, lumbar puncture, biopsy or trauma to internal organs within the previous 30
- •23. Major trauma at the time of stroke
- •24. Head trauma within the previous 90 days.
- •25. Known bleeding diathesis.
- •26. Baseline platelet count < 100 X 109/L.
- •27. Blood glucose > 400mg/dl or <50 mg/dl if administration of glucose does not rapidly reverse neurological deficit
- •Exclusion criteria that may potentially interfere with outcome assessment
- •28. Life expectancy <3 months
- •29. Other serious illness that in the opinion of the investigator may confound clinical assessment (e.g. hepatic, cardiac, or renal failure, advanced cancer)
- •Exclusion criteria related to concomitant medication
- •30. If treatment with tPA is indicated (In the 0-3 hours post-stroke time window)
- •31. Treatment with rtPA or any other thrombolytic agent for the qualifying stroke
- •32. Administration of intra-arterial or systemic thrombolytic therapy in previous 7 days
- •33. Need for antiplatelet agent, unfractionated or heparin-related products, direct thrombin inhibitor, oral anticoagulant within 24 hours after treatment bolus.
- •34. Treatment with low molecular weight heparin, direct thrombin inhibitor, or GPIIb/IIIa antagonists within 48 hours prior to randomisation
- •35. Treatment with vitamin-K antagonists or heparin (or heparin-related
研究者
相似试验
进行中（未招募）
不适用
A Multi-Centre, Double-Blind, Placebo-Controlled, Parallel-Group Induction-Design Study to assess the Clinical Effect of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic HypotensioEUCTR2008-002855-26-ATChelsea Therapeutics Inc176
进行中（未招募）
不适用
A Multi-Centre, Double-Blind, Placebo-Controlled, Ascending-Dose, Clinical Trial of Intra-venous Microplasmin Administration in Patients with Acute Ischemic Stroke - MITI-IVEUCTR2005-001074-27-BEThromboGenics Ltd.40
进行中（未招募）
不适用
A Multi-Centre, Double-Blind, Placebo-Controlled, Parallel-Group Induction-Design Study to assess the Clinical Effect of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic HypotensioSymptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (Pharmacodynamic, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy.EUCTR2008-002855-26-DEChelsea Therapeutics Inc176
进行中（未招募）
不适用
A Multi-Centre, Double-Blind, Placebo-Controlled, Ascending-Dose, Clinical Trial of Intra-venous Microplasmin Administration in Patients with Acute Ischemic Stroke - MITI-IVEUCTR2005-001074-27-ATThromboGenics Ltd.40
进行中（未招募）
不适用
A Multi-Centre, Double-Blind, Placebo-Controlled, Parallel-Group Induction-Design Study to assess the Clinical Effect of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic HypotensioSymptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (Pharmacodynamic, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy.EUCTR2008-002855-26-CZChelsea Therapeutics Inc176